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The injection of plasmid DNA encoding hepatitis B virus (HBV) envelope proteins in mouse muscle leads to the induction
of specific humoral and cellular immune responses. Most studies on DNA-based immunization have used viral promoters to
drive antigen expression. In this study, we compared the efficiency of a muscle-specific promoter, the human desmin gene
promoter, with the commonly used cytomegalovirus (CMV) early gene promoter. We showed that increased in vitro
expression of HBV envelope proteins from the human desmin gene promoter has no effect on the in vivo immune response
even after the injection of as little as 10 mg of DNA. The injection of vectors encoding HBV envelope proteins under the
control of either the human desmin gene promoter or the CMV promoter induced humoral and cytotoxic immune responses
at comparable levels and of the same duration. The recruitment of antigen-presenting cells to the DNA injection site by
pretreatment of muscle with a necrotizing agent increases the precocity and the intensity of the responses, particularly when
the nonspecific CMV vector was used. © 1999 Academic Press
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HINTRODUCTION
Genetic, or DNA-based, immunization can be defined
s the in vivo delivery of an antigen-encoding expression
ector into a given tissue for the purpose of the induction
f an immune response. This novel form of immunization
esults in de novo production of correctly folded and
lycosylated protein antigens and in certain respects
imics the actions of live attenuated or recombinant
irus vaccines. As a consequence, this mode of immu-
ization may mimic natural infection and induces a pro-
ective immune response. Indeed, in most of the studies
o date, DNA-based immunization has been found to
esult in a full range of immune responses, including
eutralizing antibodies, cytotoxic T lymphocytes (CTL), T
ell help, and (where evaluation was possible) protection
gainst challenge (Donnelly et al., 1997; Robinson and
orres, 1997; Tighe et al., 1998).
Although several DNA vaccines have been shown to
e effective in nonhuman primates (Letvin et al., 1997;
oyer et al., 1997), in most cases multiple injections were
ecessary to induce adequate immunity. In addition,
here generally is a need to reduce the dose of injected
NA and to increase the efficacy and the longevity of the
esponse. Genetic vaccines have been administered by
variety of routes, but most studies have focused on
ither the intradermal (gene-gun immunization) or the
ntramuscular route. To improve DNA uptake, intramus-
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74ular injection has often been performed after a pretreat-
ent of the muscle with a necrotizing agent like cardio-
oxin (Davis et al., 1993b) or bupivacaine (Vitadello et al.,
994).
In this study, we compared the commonly used cyto-
egalovirus (CMV) early gene promoter with a muscle-
pecific promoter derived from the human desmin gene
Li and Paulin, 1991). This was performed in conditions
ith and without muscle regeneration. Desmin is a mus-
le-specific member of the intermediate filament protein
ultigene family. It was previously demonstrated that the
equence including 228 bp upstream of the transcription
nitiation site is sufficient to confer low-level muscle-
pecific expression. High-level expression of the gene
epends on a 280-bp muscle-specific enhancer (Li and
aulin, 1991). This enhancer functions not only in myo-
ubes but also in myoblasts via the action of two inde-
endent activating regions. Previous experiments in vitro
nd in vivo (Li et al., 1993) have demonstrated that these
egulatory sequences of human desmin gene function
pecifically in skeletal muscle.
We previously developed a murine model for DNA-
ased immunization against hepatitis B virus (HBV)
Davis et al., 1993; Michel et al., 1995). Intramuscular
njection of a plasmid DNA expression vector encoding
BV envelope proteins results in synthesis of hepatitis B
urface antigen particles (HBsAg) by the transfected
uscle fibers and in long-term induction of anti-HBsAg
ntibodies that are responsible for protection against
BV infection in human. DNA-based immunization using
BsAg-expressing plasmids also gives rise to high lev-
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75MUSCLE-SPECIFIC VECTORS FOR DNA VACCINATIONls of CTL in mice (Davis et al., 1995) and nonhuman
rimates (Le Borgne et al., 1998). This specific CTL re-
ponse is required in human for viral clearance to occur
Chisari, 1995).
Here, we compare the humoral and cellular responses
btained after DNA-mediated immunization using plas-
id constructs encoding different forms of the HBsAg
rotein and containing either the viral human CMV early
ene promoter or the human desmin gene promoter. We
ind that muscle cell-restricted expression of the antigen
riven by the human desmin gene promoter gives hu-
oral and CTL responses comparable to those achieved
ith the CMV promoter. However, the use of the viral
romoter in regenerating muscle reduces the onset time
f the response and increases the intensity of the im-
une response.
RESULTS
BsAg expression after in vitro and in vivo
ransfection
Mouse myoblasts C2C12 were transiently transfected
ith each of the HBV envelope protein expression vec-
ors (see Materials and Methods and Fig. 1), and the
BsAg in the culture supernatant was quantified by an
LISA 3–24 days after transfection. As shown in Fig. 2, all
onstructs lead to the secretion of HBsAg particles in the
upernatant that persisted for at least 24 days. Immuno-
taining with an anti-troponin-T revealed that the muscle
ells had a myoblast phenotype from the beginning of
ulture to day 9 and a myotube phenotype from day 9 to
ay 24 after transfection (data not shown). This indicates
hat secretion of particles occurs in both stages of mus-
FIG. 1. Schematic diagram of expression vectors coding for the HBV e
romoter) or the human desmin gene enhancer and promoter. The H
nitiation codons and the TAA stop codon. The expected protein produ
nd represent the small (S) and the middle (M) HBV envelope proteinsnvelope proteins. The plasmids contain either the CMV early promoter (CMV
BV pre-S2 and S sequences are indicated along with the two in-frame ATG
cts are indicated as thick gray lines below the respective coding sequencesle cell differentiation (i.e., in myoblasts and myotubes). mFIG. 2. Secretion of HBsAg particles by C2C12 mouse myoblasts
ransiently transfected with vectors containing the CMV promoter or the
uman desmin gene promoter. The C2C12 cells were transfected with
lasmids encoding (A) the small HBV protein (pCMV-S, open columns;
D-S, shaded columns) or with plasmids encoding (B) the small and the
iddle proteins (pCMV-S2.S, filled columns; pD-S2.S, hatched col-
mns). The accumulation of secreted HBsAg particles in the superna-
ant was followed from day 0 to day 24. HBsAg was expressed in ng/ml.
ach value is the mean 6 SEM of four different transfection experi-
ents. The cells had myoblast phenotype from day 0 to day 9 and
yotube phenotype from day 9 to day 24.
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76 LOIRAT ET AL.The kinetics of particle secretion varied with the vec-
ors. When the muscle cells were transfected with plas-
ids encoding the small envelope protein (S) only, ten-
old more HBsAg was detected in supernatants from
ells transfected with the pD-S plasmid containing mus-
le-specific promoter compared with the plasmid
CMV-S containing the viral promoter (Fig. 2A). It is
oteworthy that for pD-S, transfected cell production of
BsAg increased from 3 to 9 days. In contrast, when the
lasmids pCMV-S2.S and pD-S2.S encoding the small
nd the middle proteins (M 1 S) were used to transfect
he C2C12 cells, similar HBsAg concentrations were
ound in supernatants (Fig. 2B), suggesting that expres-
ion of the middle protein could affect protein secretion
rom pD-S2.S-transfected cells.
In addition, we checked the presence of the individual
BsAg polypeptides because due to the intact internal
TG start codons, it was likely that the particles would be
omposed of a mixture of two different envelope pro-
eins. Analysis by solid-phase sandwich ELISA for pre-S2
ntigen (Michel et al., 1995) revealed that particles se-
reted by C2C12 cells transfected with pD-S2.S or pCMV-
2.S plasmids contained pre-S2 epitopes. Moreover, the
roportion of pre-S2 epitopes was the same for both
ypes of plasmid-encoded HBsAg particles (data not
hown).
Because significant differences were observed in vitro
n HBsAg expression, we measured the level of HBsAg in
era from mice injected in mature muscle with 100 mg of
NA plasmids containing either the muscle-specific or
he CMV promoter. We found comparable amounts of
BsAg in sera collected 4 and 8 days after injection
around 500 pg/ml).
n vivo humoral response to HBsAg in DNA-
mmunized mice
We previously described the induction of a strong and
FIG. 3. Antibody response in sera from mice immunized with 10 mg
mmunized by a single intramuscular injection of (A) 10 mg of plasmid
pCMV-S, open columns) or the human desmin gene promoter (pD-S, s
nvelope proteins under the control of either the CMV promoter (pCMV
olumns). Results are expressed as mean of ELISA 6 SEM titers of toustained humoral response to HBsAg in mice after a lingle intramuscular injection of 100 mg of pCMV-S or
CMV-S2.S DNA (Michel et al., 1995). To fully appreciate
ifferences in antibody production between vectors con-
aining a muscle-specific promoter and vectors with the
MV promoter, mice were given a single injection of only
0 mg of DNA delivered into normal tibialis muscles. Sera
btained at different time intervals after injection were
nalyzed for the anti-HBs antibody responses (Fig. 3). All
njected mice produced antibodies specific to HBsAg
articles. These were first detected at low levels 2 weeks
fter DNA injection and continued to increase for 12
eeks thereafter. The use of different promoters (i.e.,
iral or muscle specific) had no significant effect on the
ntibody response. However, at early times, antibody
iters are higher in mice injected with plasmids encoding
he middle and small envelope proteins than in those
njected with vectors encoding the small protein only.
his could be ascribed to the presence of pre-S2-specific
ntibodies because we have previously shown that such
ntibodies are present in the sera from mice injected
ith pCMV-S2.S DNA (Michel et al., 1995).
BV-specific cytotoxic T cell responses using
ifferent vector constructs
Injection into normal muscle of 10 mg of plasmid DNA
rom vectors containing the human desmin or the CMV
romoter and sequences encoding HBV envelope pro-
eins efficiently primed a CTL response to HBsAg in
ALB/c mice (Fig. 4). Splenic effector cells from DNA-
njected mice specifically lysed autologous, HBsAg-ex-
ressing P815/S transfectants but not untransfected P815
arget cells. These responses were obtained after in vivo
riming with DNA vectors expressing either the small or
he small plus the middle HBV envelope proteins fol-
owed by in vitro stimulation with the well-characterized
BsAg T-cell epitope S28–39. To assess the relative
fficiency of both promoters to induce a persistent cel-
A plasmid given in normal muscle. Groups of six BALB/c mice were
ng the small envelope protein under the control of the CMV promoter
columns) or (B) 10 mg of plasmid encoding the small and the middle
illed columns) or the human desmin gene promoter (pD-S2.S, hatched
i-HBs Ig in mice sera collected 1–12 weeks postimmunization.of DN
encodi
haded
-S2.S, fular immune response, HBsAg-specific CTL responses
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77MUSCLE-SPECIFIC VECTORS FOR DNA VACCINATIONere followed 1–12 weeks after immunization. No CTL
ctivities were detected 1 week after DNA injection (data
ot shown). However, immunization with 10 mg of plas-
id containing the human desmin or the CMV promoter
eproducibly primed CTL responses from 3 weeks to up
o 12 weeks after a single injection (Fig. 4). No difference
n specific lysis or in duration of CTL activities was
bserved between plasmids, and the most potent CTL
esponses were observed 6 weeks after gene transfer
ith plasmids expressing the two envelope proteins.
nfluence of injected DNA dose and of muscle
retreatment on the onset of the cytotoxic response
It was previously shown that cardiotoxin allows the
egeneration of muscle fibers followed by a regeneration
nd, consequently, by an increased efficiency of muscle
ell transfection (Davis et al., 1993b). Recruitment of
ntigen-presenting cells (APC) (macrophages and den-
ritic cells) was also observed during the regeneration at
he site of injection (Pimorady-Esfahani et al., 1997).
To evaluate whether the amount of injected DNA
nd/or the pretreatment of the muscle could lead to an
arlier cytotoxic response, 10 or 100 mg of pCMV-S2.S
FIG. 4. Kinetics of the cytotoxic T cell response in mice primed to H
MV promoter (F, E) or the desmin promoter (f, M) and expressing
bottom) was injected once into normal muscle. Spleen cells were obta
pecific cytolytic activity against transfectants expressing the small pr
ean values from two or three individual mice.nd pD-S2.S DNAs were injected into mature or regen- urating muscle. The cytotoxic responses were compared
week after immunization. Splenic effector cell lysis
ctivity was tested 1 week after immunization against
utologous P815/S transfectants or untransfected P815
arget cells (Fig. 5).
After the injection of 10 mg of pCMV-S2.S or pD-S2.S
lasmid DNA in normal muscle, no significant specific
ysis against P815/S targets was detected even at an
ffector-to-target cell ratio (E/T) of 100/1. Increasing the
mount of DNA from 10 to 100 mg in normal muscle did
ot lead to detectable CTL activity after 1 week, indicat-
ng that the amount of injected DNA is not the major
actor affecting the onset of CTL induction.
In contrast, when muscle was pretreated with a ne-
rotizing agent like cardiotoxin, 10 mg of the ubiquitous
CMV-S2.S vector was sufficient to induce a clearly de-
ectable cytotoxic response 1 week after injection,
hereas pD-S2.S was unable to induce a significant
ellular cytotoxicity.
Injection of 100 mg of either pCMV-S2.S or pD-S2.S
lasmid into a regenerating muscle resulted in strong
TL induction. However, the intensity of CTL activity
fter muscle pretreatment depended on the vector
y DNA-based immunization. Ten mg of plasmids containing either the
all HBV envelope protein (top) or the small and the middle proteins
om immunized mice 3, 6, or 12 weeks after injection and assayed for
815/S, F, f) or P815 cells (E, M). The specific lysis values representBsAg b
the sm
ined fr
otein (Psed for immunization. Mice receiving the pD-S2.S
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78 LOIRAT ET AL.ector displayed weaker CTL activity than those re-
eiving the pCMV-S2.S vector (Fig. 5). These results
how that under our experimental conditions, cardio-
oxin pretreatment is required for the early induction of
ytotoxic T lymphocytes. Increasing the amount of
njected DNA enhances this effect. Moreover, with the
uscle-specific vector, both conditions are required to
nduce early CTL activity.
inetics of the CTL activity induced by injection of
00 mg of DNA after muscle regeneration
We next evaluated the effects of muscle pretreatment
n the longevity of the immune response. Cytotoxic T cell
esponses in mice injected with 100 mg of pCMV-S2.S or
D-S2.S plasmid DNA in regenerating muscle were fol-
owed 1–12 weeks after injection (Fig. 6). At an E/T of
0:1, a significant difference between both plasmids was
bserved 1 week after injection, as described above (see
ig. 5). In contrast, the two plasmids induced similar
ellular responses at later times. Specific lysis was
quivalent in mice injected 3 or 12 weeks earlier with
CMV-S2.S or pD-S2.S. For the pD-S2.S plasmid, maxi-
um CTL activity was attained 3 weeks after injection,
hereas for the CMV vector, CTL activity peaked after 1
eek, and slowly decreased thereafter. Thus in regen-
rating muscle, antigen expression driven by the desmin
romoter resulted in a delayed but efficient CTL re-
FIG. 5. Effect of amount of injected DNA and of muscle regeneration
f plasmid DNA (pCMV-S2.S or pD-S2.S) injected in normal muscle or in
days before DNA immunization. Splenocyte cytotoxic activity was mea
arget cells. The specific lysis values represent mean values 6 SEM fponse. fumoral response to HBsAg in mice injected with
00 mg of DNA in regenerating muscle
Anti-HBs antibody response was followed in the
era of mice injected with 100 mg of DNA in regener-
ting muscle (i.e., under conditions inducing the stron-
est CTL response; see Fig. 5). All mice immunized
ith the pCMV-S2.S vector seroconverted 1 week after
njection. In contrast, injection of the pD-S2.S vector
ontaining the muscle-specific promoter lead to 100%
eroconversion after 4 weeks (data not shown). More-
ver, none of the pD-S2.S-injected mice had detect-
ble antibody 1 week after immunization. Titers of total
nti-HBs immunoglobulin correlated with the differ-
nce observed for seroconversion (Fig. 7). During the
2 weeks of the survey, antibody titers were consis-
ently two to three times higher in mice injected with
CMV-S2.S than in those injected with pD-S2.S. As
xpected, injection of 100 mg DNA in regenerating
uscle induced higher antibody titers than injection of
0 mg of DNA in normal muscle, leading to a
ixfold and a threefold increase in titer for the pCMV-
2.S and for pD-S2.S, respectively (compare Figs. 3B
nd 7).
These observations indicate that the expression of
oreign antigen driven by an ubiquitous promoter like
MV promoter is determinant not only for early CTL
nduction but also for time of seroconversion, as well as
rly cytotoxic T cell response. Mice were immunized with 10 or 100 mg
rating muscle. Regeneration was performed by injection of cardiotoxin
1 week after immunization against P815/S target or P815 untransfected
ee individual mice tested at an effector-to-target ratio of 100/1.on ea
regene
sured
rom thror level of antibody titers.
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79MUSCLE-SPECIFIC VECTORS FOR DNA VACCINATIONDISCUSSION
Even if skeletal muscle cells are not generally recog-
ized for their secretory function or for their APC capa-
ility (Hohlfeld and Engel, 1994), the muscle tissue con-
titutes, together with the epidermis, one of the most-
sed target for DNA-based immunization. Direct injection
f expression vectors into muscle cells induces synthe-
is and secretion of recombinant protein (Wolff et al.,
990; Naffakh et al., 1996). The high vascularity of this
rgan permits the rapid entry of the expressed protein
nto circulation. Moreover, because of its accessibility,
uscle tissue offers important advantages, such as the
ossibility of direct injection, biopsy, or cell graft.
In this work, we explored the potentialities of a mus-
le-specific vector containing the human desmin gene
nhancer and promoter unit for DNA-based immuniza-
ion. We find that in normal muscle, at a low dose of
njected DNA (10 mg), the muscle-specific vectors in-
uced humoral and cellular immune responses against
BsAg similar to those induced by ubiquitously ex-
ressed vectors containing the CMV early gene pro-
oter.
Specific expression of genes placed under the control
f the human desmin gene enhancer and promoter unit
ad been studied previously in different cell types in vitro
Li and Paulin, 1993). Thus we evaluated the efficiency of
ur constructs by in vitro transfection of a muscle cell
ine. In vitro transfection of mouse myoblasts with plas-
FIG. 6. Kinetics of the cytotoxic T cell response in mice injected with
00 mg of DNA in regenerating muscle. Mice were immunized once
ith plasmids containing the CMV promoter (pCMV-S2.S) or desmin
romoter (pD-S2.S). Spleen cells were obtained from immunized mice
, 3, or 12 weeks after injection and assayed for specific cytolytic
ctivity against P815 cells pulsed with the peptide S 28–39 (P8151S) or
npulsed targets (P815). The specific lysis values represent mean
alues 6 SEM from three individual mice tested at an effector-to-target
atio of 30/1.ids encoding HBV envelope proteins resulted in the wecretion of HBV envelope particles in cell supernatant.
nterestingly, for plasmids encoding the small envelope
rotein only, the desmin promoter-enhancer induces bet-
er expression than the CMV promoter. Due to the mus-
le-specific transcription factors present in myoblasts
nd myotubes, the desmin enhancer-promoter is placed
n a more appropriate environment than the viral pro-
oter (Li and Paulin, 1993). After transfection with
D-S2.S and pCMV-S2.S vectors encoding the middle
nd the small HBV envelope proteins, there was no
ignificant difference in HBsAg particles present in cell
upernatant. It was previously shown that the middle
rotein can be retained into cells when expressed from
trong promoters (Chow et al., 1997). This could ex-
lained the weak accumulation of secreted particles in
he supernatant after transfection with pD-S2.S. Glyco-
ylation of viral proteins in muscle cells has not been
reviously studied and was also shown to affect HBsAg
article secretion (Mehta et al., 1997; Werr and Prange,
998). Although remarkable differences in antigen ex-
ression from various vectors were observed in vitro,
imilar antibody responses were induced in vivo by the
our vectors used. This confirmed that antigen secretion
s not required for the induction of an immune response
n vivo (Haddad et al., 1997; Leclerc et al., 1997; Torres et
l., 1997).
DNA-based immunization with vectors containing the
esmin gene enhancer-promoter in mature mouse mus-
le also gave similar cellular immune responses to those
chieved with vectors containing the viral CMV promoter.
ctually, it was shown in transgenic mice that in vivo
ransgene expression of b-galactosidase driven by reg-
latory sequences of the human desmin gene was re-
tricted to skeletal muscles only and was not detected in
mooth and cardiac muscle cells (Li et al., 1993). In
ontrast, injection of plasmid containing the CMV pro-
oter allowed additional b-galactosidase expression in
FIG. 7. Antibody response in mice immunized with 100 mg of DNA
lasmid in regenerating muscle. Groups of six BALB/c mice were given
single injection of plasmids pCMV-S2.S (F) or pD-S2.S (M) in muscle
reated 5 days previously with cardiotoxin. Results are expressed as
ean ELISA titer 6 SEM of total anti-HBs Ig of mice sera collected 1–12
eeks postimmunization.
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80 LOIRAT ET AL.he mesenchymal cells surrounding the myofibers (D.
aulin and M. Kazanji, unpublished results). These ob-
ervations suggest that restriction of antigen expression
o muscle cells is sufficient to induce humoral and cel-
ular immune responses (Ulmer et al., 1996). However, for
ectors encoding HBsAg, we have detected this antigen
n sera from DNA-injected mice independently of the
ector use for immunization. This indicates that the an-
igen was secreted or otherwise released from muscle
ells after intramuscular injection (Davis et al., 1997), and
hus it can be found at a low level in the serum. More-
ver, this antigen consists of proteins associated with
ellular lipids to form particles that can enter the APCs
nd thus be processed via the endogenous pathway to
nduce CTLs (Schirmbeck et al., 1994). Because muscle
ells are not able to prime CTL response by themselves,
he high level of cytotoxic response observed after a
ingle injection into mature muscle with 10 mg of DNA
ectors containing the human desmin promoter could be
xplained by capture of HBsAg particles by APCs.
Muscle regeneration results from the proliferation of
atellite cells, with their fusion into multinucleated myo-
ubes followed by the transformation of myotubes into
ature muscle fibers. Consequently, an increased ex-
ression of injected foreign gene was observed (Vita-
ello et al., 1994). In regenerating muscle, the presence
f higher amounts of specific transcription factors should
esult in an enhancement in gene transcription from the
esmin promoter. Moreover, it was shown that full activ-
ty of the human desmin enhancer requires the presence
f two muscle-specific transcriptional factors (Li and
aulin, 1993). Nevertheless, in regenerating muscle, in-
ection of 10 mg of muscle-specific vectors did not induce
CTL response after 1 week, whereas in mice injected
ith the CMV vector, a CTL response was clearly detect-
ble. This indicates that the level of gene expression is
ot a major factor affecting CTL induction. In contrast,
fter injection of pCMV-S2.S in regenerating muscle, CTL
nduction did occur in 1 week, indicating that other mech-
nisms are involved. An important effect of muscle re-
eneration is certainly the recruitment of APCs (i.e., mac-
ophages and dendritic cells) to the site of injection. The
egeneration involves inflammation, and thus macro-
hages are present to eliminate destroyed fibers or dam-
ged cells. The increased presence of APCs at the DNA
njection site could allow a more efficient uptake of
ntigen released from muscle cells. It has been sug-
ested that during intramuscular injection of DNA, the
uscle may act as a reservoir for antigen production (Fu
t al., 1997), but that muscle cells are not professional
PCs and cannot be converted into APCs even after
otransfection with DNA encoding costimulatory mole-
ules (Iwasaki et al., 1997). The key cells in the induction
f the immune response are in fact resident bone mar-
ow-derived APCs (Torres et al., 1997). Alternatively, or in
ddition, APCs could be directly transfected (Condon et cl., 1996; Chattergoon et al., 1998), or could take up the
njected plasmid DNA (Casares et al., 1997). Moreover, it
as shown that injection of a very small number of
ransfected APCs (500–1000) is sufficient to initiate a
ide variety of immune responses (Timares et al., 1998).
ecause expression of the encoded proteins in APCs
equires vectors containing ubiquitously active promot-
rs, the early CTL induction after pCMV-S2.S, but not
fter pD-S2.S, injections suggests that APCs may have
een transfected.
It has been shown that injection of increased amount
f DNA results in a higher plasmid uptake and subse-
uent expression of the encoded antigen (Levy et al.,
996). However, in mature muscle, increasing the
mount of HBsAg-encoding plasmid from 10 to 100 mg
id not produce a significant increase in CTL 1 week
fter injection (see Fig. 5). This further confirms that the
evel of antigen expression is not determinant for CTL
nduction. In contrast, in regenerating muscle, the in-
rease in injected DNA clearly resulted in a enhance-
ent of early CTL (Fig. 5). Moreover, this effect was
bserved for ubiquitously active as well as for muscle-
pecific vectors. The CTL detected after injection of mus-
le-specific vector may only result from the capture,
rocessing, and presentation of the antigen secreted by
he transfected muscle cells by the professional APCs
ecruited by the cardiotoxin treatment. In contrast, the
TL detected after injection of CMV vector may result
rom both synthesis of endogenous antigen and capture
f exogenous antigen or DNA.
In summary, we have shown that combining exoge-
ous and endogenous antigen processing by profes-
ional APCs provides optimal conditions for the induc-
ion of efficient humoral and cytotoxic responses.
In contrast, increasing antigen production by muscle
ells has no major effect on the intensity of the immune
esponse, so in our model, the human desmin gene
romoter was not appropriate to improve DNA immuni-
ation but it could be used for tissue-targeted gene
herapy. Thus further improvements in DNA vaccines will
ocus on the recruitment of APCs to the injection site and
n the efficiency of their transfection. The cardiotoxin will
ot be appropriated for human use, but other agents like
upivacaine have been already used safely in a human
rial to enhance in vivo transfection and gene expression
MacGregor et al., 1998). Classic adjuvants (Sasaki et al.,
998), as well as CpG immunostimulatory motifs (Sato et
l., 1996; Chu et al., 1997), have already been tested in
nimals. The direct transfection of APCs (skin Langer-
ans’ cells, dendritic cells, or macrophages) has been
chieved by using the gene-gun intradermal or intramus-
ular injection of DNA (Akbari et al., 1999; Casares et al.,
997; Chattergoon et al., 1998; Condon et al., 1996). Other
trategies, such as targeting of specific surface mole-
ules on APCs (Langermann, 1998; Boyle et al., 1998)
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sing.
MATERIALS AND METHODS
BsAg expression vectors
Four plasmids containing part of the envelope coding
omain of the HBV genome (ayw subtype) were con-
tructed (Fig. 1). In two plasmids (pCMV-S, pCMV-S2.S)
Michel et al., 1995), these domains were placed under
he transcriptional control of the human CMV immediate-
arly promoter, whereas the pD-S and pD-S2.S con-
tructs were driven by the human desmin enhancer and
romoter. To obtain pD-S and pD-S2.S, the CMV pro-
oter of pCMV-S and pCMV-S2.S was replaced by a
.6-kb fragment that contains 0.3-kb enhancer and 0.3-kb
romoter of human desmin gene. To obtain the maximal
xpression, we removed the transcriptionally negative
egion between 2693 and 2228 bp (Li and Paulin, 1991)
n the constructions. In pCMV-S2.S and pDS2.S con-
tructs, the internal ATG start codon remained intact and
llowed the expression of the small envelope protein,
ogether with the middle envelope protein. The two other
lasmids pCMV-S and pD-S allowed the expression of
he small envelope protein only. In all the constructs, the
olyadenylation signal is provided by downstream HBV
ntranslated sequences, and a signal for secretion is
ncoded within the S sequence. Plasmid DNAs used for
oth in vitro or in vivo transfection were prepared using
iagen DNA purification columns (Endofree Plasmid Kit;
iagen, Hilden, Germany).
n vitro transfection with HBsAg expression vectors
Transfection of muscle cell line. Mouse myoblasts
2C12 (ATCC) were cultured in Dulbecco’s modified Ea-
le’s medium (DMEM) supplemented with penicillin (100
U/ml), streptomycin (100 mg/ml), and 20% FCS. For trans-
ection, 75 3 103 cells were cultured in 12-well tissue
ulture plates. At the day of transfection, the cells
eached 70% confluency. The cells were washed twice
ith medium without serum before transfection to re-
ove serum. Plasmid DNA transient transfections were
erformed using Tfx 50 (Promega, Madison, WI). One mg
f plasmid DNA was complexed with 3 ml of Tfx 50 in 400
l of DMEM without serum. After a 15-min incubation at
oom temperature, the DNA–lipid complex was added to
he cells. After a 1-h incubation period at 37°C, 600 ml of
resh medium with 20% of FCS was added. At different
imes after transfection, supernatants were harvested for
uantification of secreted HBsAg particles and replaced
y fresh medium. Each transfection experiment was per-
ormed in quadruplicate. To evaluate the stage of cell
ifferentiation during transfection, immunostaining was
erformed on control cells using an anti-troponin-T anti-
ody (Sigma Chemical Co, St Louis, MO). Troponin-T is (xpressed in differentiated muscle cells, the myotubes.
egative cells were considered as myoblasts.
Detection of HBsAg by specific ELISA. The HBsAg
articles secreted from transfected cells were quantified
sing a commercial ELISA kit (Monolisa, Diagnostic Pas-
eur, France). Pre-S2 antigenic determinants present on
BsAg particles were quantified by a specific sandwich
LISA (Michel et al., 1995).
NA-based immunization of mice
HBsAg expression vectors were injected directly into
ormal or regenerating tibialis anterior muscles of 6- to
-week-old (19–21 g) female mice of the BALB/c strain
H-2d; Iffa Credo, France) as previously described (Davis
t al., 1993b; Mancini et al., 1996). Each tibialis anterior
uscle was injected with 50 ml of DNA at 1 mg/ml or 100
g/ml in PBS such that each animal received a total of
00 or 10 mg of DNA. All intramuscular injections were
arried out under anesthesia (sodium pentobarbital 75
g/kg IP).
easurement of in vivo anti-HBs production
At various times after gene transfer, blood was col-
ected from mice by retrobulbar puncture using heparin-
zed glass pipettes, and serum was recovered by cen-
rifugation (10 min at 2000g). Sera were tested for reac-
ivity against HBsAg particles, and antibodies specific to
BsAg were quantified by end-point dilution ELISA as-
ay. The HBsAg particles were coated onto the plates at
mg/ml, and ELISA assays were performed as described
reviously (Mancini et al., 1993). Adsorbed antibodies
ere detected with anti-mouse Ig conjugated to horse-
adish peroxidase (Amersham, Buckinghamshire, UK).
ouse sera were tested individually, and titers were the
ean 6 SEM of at least three determinations. End-point
iters were defined as the highest serum dilution that
esulted in an absorbance values (OD 492 nm) two times
reater than that of nonimmune serum with a cutoff
alues of 0.05.
easurement of CTL activity
Spleens were removed 1, 3, 6, or 12 weeks after DNA-
ased immunization. Splenocytes were cultured (10 3
06 on 24-well plate) in a-MEM (GIBCO, Grand Islan, NY)
upplemented with 10 mM HEPES, nonessential amino
cids, 1 mM sodium pyruvate, 5 3 1025 M b-mercapto-
thanol, antibiotics, and 10% FCS. These cells were stim-
lated for 5 days with 5 mg/ml S-derived peptide (amino
cids 28–39 starting from the first methionine of the
mall envelope protein) corresponding to a H-2d-re-
tricted epitope (Ando et al., 1994). Effector cells were
sed in a cytotoxicity assay after 7 days of culture.
pecific cytolytic activity of cells was tested in short-term
51Cr-release assay against transfected targets (P815/S)
Major et al., 1995), P815 cells were pulsed with the S
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82 LOIRAT ET AL.eptide (15 mg/ml), and P815 cells were used as negative
ontrol. After a 4-h incubation at 37°C, supernatants
ere collected and counted on a beta counter (Buseyne
t al., 1996). Spontaneous and maximum releases were
etermined from wells containing either medium alone
r lysis buffer (5% Triton X-100, 1% SDS). Specific lysis
as calculated as (experimental release 2 spontaneous
elease)/(maximum release 2 spontaneous release) 3
00 for each experiment. The specific lysis was calcu-
ated for each point in triplicate.
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